Summary: Alzheimer’s disease affects more than 55 million people worldwide and has traditionally been associated with toxic protein buildups and chronic brain inflammation. A recent review highlights a crucial role for adaptive immune cells—T cells and B cells—in the disease process. These cells can either exacerbate neural injury or provide protective effects depending on their state and interactions within the brain.
This growing evidence reframes Alzheimer’s disease as not only a disorder of amyloid plaques and tau tangles but also one of immune imbalance. Therapies that restore or rebalance immune function may provide more targeted and effective ways to slow progression or reduce risk.
Key Facts
- Immune involvement: Adaptive immune cells, including T and B lymphocytes, can cross the blood–brain barrier and influence Alzheimer’s progression.
- Dual roles: Some adaptive immune responses appear to worsen inflammation and neurodegeneration, while others may clear toxic proteins or support neuronal resilience.
- Therapeutic potential: Future strategies may include immune-modulating therapies, vaccines, or personalized approaches that account for an individual’s immune profile and genetic risk.
Source: Chinese Medical Journals Publishing House Co
Alzheimer’s disease (AD) is a leading cause of dementia worldwide, impacting over 55 million people and placing an increasing burden on families and healthcare systems as populations age.
Despite extensive research, there is no cure for AD, and currently available treatments provide only limited symptomatic relief. A deeper understanding of the mechanisms driving the disease is essential to develop more effective therapies.
Traditionally, Alzheimer’s has been characterized by two hallmark protein pathologies: extracellular plaques formed by amyloid-beta and intracellular neurofibrillary tangles formed by tau protein. These abnormalities disrupt neuronal communication and contribute to cognitive decline. More recently, chronic neuroinflammation has been recognized as a core aspect of disease biology.
Neuroinflammation was long viewed as the work of the brain’s innate immune cells, such as microglia and astrocytes. New research, however, points to a substantial role for the adaptive immune system. T cells and B cells, which typically mediate long-term and antigen-specific immune responses, are now implicated in Alzheimer’s-related inflammation and pathology.
Researchers from Fujian Medical University Union Hospital and the Fujian Key Laboratory of Molecular Neurology compiled and analyzed decades of studies to assess how adaptive immunity contributes to Alzheimer’s. Their review, led by Dr. Xiaochun Chen and published in the Chinese Medical Journal, synthesizes current evidence on immune cell entry into the brain, cellular interactions, and the consequences for disease progression.
The adaptive immune system can access the central nervous system when the blood–brain barrier is compromised. Once inside, T and B cells interact with resident brain cells and myeloid cells in complex ways. Some T cell subsets secrete pro-inflammatory cytokines that can amplify neuronal damage, while other subsets may help regulate inflammation and support clearance of toxic proteins. Similarly, B cells may produce antibodies that facilitate removal of amyloid but can also participate in harmful immune reactions under certain conditions.
“Adaptive immunity acts like a double-edged sword,” says Dr. Chen. “Some adaptive responses appear to accelerate cognitive decline, while others seem to protect neurons. Understanding how to shift that balance toward beneficial immune activity is an important goal for therapeutic development.”
This perspective has direct implications for treatment strategies. Immunotherapies that target amyloid have produced mixed results; they have reduced plaque burden in some patients but delivered variable clinical benefit and sparked debate over risks and patient selection. The review argues that a more comprehensive approach—one that includes modulation of adaptive immune responses—could improve outcomes.
Potential strategies discussed include therapies designed to rebalance T and B cell function, vaccine approaches that stimulate protective immunity, and personalized interventions tailored to a patient’s genetic and immunological profile. However, the authors caution that much remains uncertain: how immune cells cross into the brain, why they behave differently among individuals, and how aging-related changes in immunity intersect with Alzheimer’s pathology all require further study.
Clarifying these mechanisms will be essential for developing precise diagnostics and safe, effective immunomodulatory treatments. As research progresses, targeting adaptive immunity could emerge as a promising avenue to prevent or slow disease progression and reduce the global burden of Alzheimer’s.
“Adaptive immunity has moved from the periphery of Alzheimer’s research to a central consideration,” Dr. Chen notes. “We are only beginning to understand its complexity, but these insights may help reshape prevention and treatment approaches.”
In summary, the review reinforces a growing consensus: Alzheimer’s disease is not solely a disorder of protein aggregates but also involves significant immune dysregulation. Integrating immune-centered perspectives into research and therapy development may provide new hope for patients, caregivers, and healthcare systems worldwide.
About this Alzheimer’s disease and immune system research news
Author: Tingting Yang
Source: Chinese Medical Journals Publishing House Co
Contact: Tingting Yang – Chinese Medical Journals Publishing House Co
Image: The image is credited to Neuroscience News
Original Research: Open access. “Adaptive immunity in the neuroinflammation of Alzheimer’s disease” by Xiaochun Chen et al. Chinese Medical Journal
Abstract
Adaptive immunity in the neuroinflammation of Alzheimer’s disease
Alzheimer’s disease (AD) is the most common cause of dementia and represents a major and growing public health challenge. Neuroinflammation is a prominent feature of AD and was traditionally ascribed to the innate immune system. Emerging evidence, however, implicates adaptive immunity—particularly T and B lymphocytes—in the neuroinflammatory processes associated with AD.
How adaptive immune responses that normally protect the body contribute to persistent inflammation and neuronal dysfunction in AD remains an open question. This review examines the roles of adaptive immunity, the cellular composition and niches involved, and how these elements contribute to disease onset and progression.
We summarize the crosstalk between adaptive immunity and the central nervous system’s innate immune components—mainly glial and myeloid cells—and their interrelationships with amyloid-β (Aβ) and tau pathology. We propose that alterations in innate immunity often reflect age-related immune changes, whereas dysregulation of adaptive immunity may drive disease-specific immune responses in AD.
Targeting adaptive immune mechanisms within the context of neuroinflammation could offer new directions for diagnostics and therapies aimed at modulating immune responses to prevent or treat Alzheimer’s disease.